CONNAUGHT OPOL LIVE OPV: FDA FINDS SEVEN OF 12 CLINICALS CONFORM
Executive Summary
CONNAUGHT OPOL LIVE OPV: FDA FINDS SEVEN OF 12 CLINICALS CONFORM to federal requirements for vaccine licensure under 21 CFR 630.11, FDA Office of Vaccines Research & Review Senior Staff Fellow Judy Beeler, MD, said during discussion at a Nov. 18 meeting of FDA's Vaccines & Related Biological Products Advisory Committee. Beeler said the PLA committee for Toronto-based Connaught, Ltd.'s trivalent live oral polio vaccine reviewed the immunogenicity data derived from 12 clinical trials. FDA analysis was based on determining seroconversion rates to find a four-fold or greater rise in type-specific neutralizing antibody, Beeler noted.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth